ClinicalTrials.gg
CompletedNCT01376076Updated Feb 8, 2012

Effects of Cariprazine on Cardiac Repolarization in Patients With Schizophrenia

A Phase 1 interventional study of Cariprazine and Risperidone/Moxifloxacin in Schizophrenia, sponsored by Forest Laboratories. Completed at 4 sites in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2012-02-08.

Sponsored by Forest Laboratories (part of AbbVie) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
129
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing cariprazine in Schizophrenia — 4 open to participants now, 4 under way, 2 of them phase 3. cariprazine · Schizophrenia.

Enrollment
12th of 23
129 · median 129
Started
2011
with 1 other
Phase 1
4 of 23
1 open now
Registered
8th of 23
by date
Lead sponsor
8 of 23
Forest Laboratories

Among the 23 studies testing cariprazine in Schizophrenia, this one is the 12th largest by enrollment, is one of 2 that started in 2011, is one of 4 in phase 1, and was the 8th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 23 studies testing cariprazine in Schizophrenia are open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About cariprazine

cariprazine: first FDA approval 2015 (VRAYLAR), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing cariprazine in Schizophrenia, or all of them as a file.
02

Study summary

This study will evaluate the effects of sequential multiple dose regimens of cariprazine on cardiac repolarization in patients with schizophrenia.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • schizophrenia
  • QTc
  • cardiac repolarization
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women, age 18 to 50, inclusive
  • Symptoms of schizophrenia or schizoaffective disorder first appearing a minimum of 1 year before screening
  • Negative pregnancy test
  • Normal physical examination results, vital signs, and clinical lab test results

Exclusion criteria

Exclusion Criteria:

  • Axis II disorder severe enough to interfere with the study
  • Smoking more than 20 cigarettes a day
  • History or presence of cardiovascular disorder
  • Pregnant/breast-feeding and/or planning to become pregnant/breast-feed
  • Imminent risk of injuring self or others or causing significant property damage
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
129 participants (actual)

Study arms

  • Experimental
    1

    Sequential, Multiple Dose, titration from 1.5mg to 18mg once daily dose of cariprazine

    Drug: Cariprazine

  • Placebo comparator
    2A

    Double blind placebo for Days 1-5, Moxifloxacin (400mg) on Day 6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-35

    Drug: Risperidone/Moxifloxacin

  • Placebo comparator
    2B

    Double blind placebo for Days 1-6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-34, Moxifloxacin (400mg) on Day 35

    Drug: Risperidone/Moxifloxacin

Interventions

  • Patients meeting all study eligibility criteria will be randomized to receive cariprazine (Group 1) 1.5 to 18 mg once daily, administered orally.

  • DrugRisperidone/Moxifloxacin

    Patients randomized to Group 2A will receive double blind placebo for Days 1-5, Moxifloxacin (400mg) on Day 6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-35.

  • DrugRisperidone/Moxifloxacin

    Patients randomized to Group 2B will receive double blind placebo for Days 1-6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-34, Moxifloxacin (400mg) on Day 35.

06

What researchers measure

Primary outcomes

  1. Heart rate-corrected QT interval (QTc)

    The effects of a therapeutic dosage (9 mg/day) and a supratherapeutic dosage (18 mg/day) of cariprazine on cardiac repolarization as determined by heart-rate-corrected QT intervals will be assessed on Day 20 and Day 34, respectively. The assay sensitivity of moxifloxacin 400 mg/day will be assessed on Day 6 and Day 35.

    Time frame: 35 days of double-blind treatment, up to 56 days total.

07

Study locations

4 sites
  • Forest Investigative Site 001
    Glendale, California 91206, United States
  • Forest Investigative Site 004
    Long Beach, California 90806, United States
  • Forest Investigative Site 002
    Willingboro, New Jersey 08046, United States
  • Forest Investigative Site 003
    Houston, Texas 77008, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2011, a primary completion of Feb 2012 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2011
First posted
Jun 20, 2011
Start
Jun 2011
Primary completionActual
Feb 2012
CompletionActual
Feb 2012
Last update
Feb 8, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01376076
Responsible party
Sponsor
First posted
Jun 20, 2011
Start date
Jun 2011
Primary completion
Feb 2012
Completion
Feb 2012
Last update
Feb 8, 2012

Study contacts

Suneeta Ahuja, PhD
study director · Forest Laboratories

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cariprazine

Start the discussion